Cancer-testis antigens: An update on their roles in cancer immunotherapy.
Several recent studies have assessed suitability of tumor antigens for immunotherapy. Based on the restricted expression pattern in somatic tissues, cancer-testis antigens (CTAs) are possible candidates for cancer immunotherapy. These antigens are expressed in various tumors including gastrointestinal, breast, skin and hematologic malignancies. To find clinical trials utilizing CTAs in cancer patients. We searched PubMed, google scholar and specific websites that registers clinical trials. A number of clinical trials have been designed to evaluate safety and efficacy of CTA-based treatments. The results of some of them have been promising. In the current literature search, we summarized the clinical trials of CTA-based therapies in cancer patients. Based on the availability of different formulations of CTA-based vaccines, future researches should compare efficiency of these modalities.